£1.8M
The financing round was led by Ahren Innovation Capital and will support the expansion of the company's in-house target discovery programme.
"OutSee’s Nomaly technology is a truly next-generation genomic analysis tool with potential to transform drug discovery using powerful data-driven insights. It allows us to interrogate smaller datasets, and even data that has already been analysed, to uncover unique target insights that until now would have remained undetected."
